Steve Harr, Sana CEO

Game change: A fron­trun­ner in the cell ther­a­py 2.0 field of­fers a first look at their lead ther­a­py. And it’s a doozy

When a pair of CAR-T pi­o­neers from Juno launched Sana Biotech­nol­o­gy back at the be­gin­ning of 2019, they had some grand and rather vague­ly de­fined plans on build­ing mul­ti­ple plat­forms to en­gi­neer cells — part of the whole cell ther­a­py 2.0 move­ment that’s at­tract­ed bil­lions of dol­lars in fi­nanc­ing.

But, like most pri­vate star­tups, CEO Steve Harr and the crew kept the pro­gram de­tails qui­et, part of the in­evitable “stealthy” ap­proach on time­lines and treat­ments you run in­to with am­bi­tious play­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.